This Article Full Text (PDF) Other Versions of this Article: AAC.00472-06v1 51/2/495    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sansone-Parsons, A. Articles by Stoltz, R. Search for Related Content PubMed PubMed Citation Articles by Sansone-Parsons, A. Articles by Stoltz, R.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.00472-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Effects of Age, Gender, and Race/Ethnicity on the Pharmacokinetics of Posaconazole in Healthy Volunteers

Schering-Plough Research Institute, Kenilworth, New Jersey, Research Solutions, Little Rock, Arkansas, and Covance GFI Research, Evansville, Indiana

^* To whom correspondence should be addressed. Email: angela.sansone{at}spcorp.com,

	Abstract

Posaconazole is a triazole antifungal for prophylaxis of invasive fungal infection and treatment of oropharyngeal candidiasis. We evaluated the effects of gender, age, and race/ethnicity (black or white) on the steady state pharmacokinetics of posaconazole in 2 studies on healthy adult subjects (18 years of age). Additionally, they explored the effect of P-glycoprotein (P-gp) expression and MDR1 genotype on posaconazole pharmacokinetics in black and in white subjects. Age, gender, and race/ethnicity had no clinically relevant effects on posaconazole pharmacokinetics. No association was observed between any MDR1 single nucleotide polymorphism and the area under the concentration-time curve of posaconazole. Posaconazole was safe and well tolerated regardless of age, gender, or race/ethnicity. In conclusion, age, gender, and race/ethnicity have no clinically relevant effects on the steady state pharmacokinetics of posaconazole in healthy adults; therefore, dosage adjustments based on these covariates are unnecessary.

This article has been cited by other articles:

• Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H (2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy 42: 1429-1438 [Abstract] [Full Text]